GlassScriptPhysician profile
Sam G Vorkpor
NPI 1700076874
$1,112.90
in general payments reported to CMS, 2019-2025
23 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $64.29 · 2021: $23.19 · 2022: $208 · 2023: $226 · 2024: $127 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159.90 | 2022-2025 | Dalvance |
| Novo Nordisk INC | $121.04 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $105.08 | 2019-2024 | |
| Lilly USA, LLC | $90.23 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Merck Sharp & Dohme LLC | $68.33 | 2022-2025 | Verquvo, Steglatro, Zerbaxa |
| Medtronic, INC. | $58.28 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $53.66 | 2019 | |
| Allergan, INC. | $51.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.33 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.32 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $38.31 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $34.82 | 2019-2025 | Spravato |
| Astellas Pharma US INC | $29.55 | 2023 | Myrbetriq, Veozah |
| Amarin Pharma, INC. | $28.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.46 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.05 | 2020 | |
| Shield Therapeutics INC | $24.60 | 2025 | |
| Amgen INC. | $23.03 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.21 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.13 | 2025 | Caplyta |
| Pfizer INC. | $13.49 | 2019 | |
| Insulet Corporation | $12.14 | 2019 | |
| Phathom Pharmaceuticals, INC. | $11.65 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Vorkpor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.